NEWS
Advancements in Patient-Centered Care
Stay up to date with the latest advancements in oral oncolytics, medically-integrated oncology, and cancer care best practices.

Minnesota Oncology First to Earn NCODA Center of Excellence Medically-Integrated Pharmacy Accreditation
May 12, 2022 |

MAINE PUSHES FORWARD WITH COPAY REFORM
May 6, 2022 |

WASHINGTON STATE ENDS LEGISLATIVE SESSION WITH WIN FOR PATIENTS
April 20, 2022 |

NCODA and XIFIN Launch New Initiative to Expand Oncology Patient Care Options
April 14, 2022 |

OHIO MAKES IT OFFICIAL: UNANIMOUS VICTORY TO BAN COPAY ACCUMULATORS
April 6, 2022 |

NCODA Now Certified To Provide Continuing Education For Pharmacists & Pharmacy Technicians
March 29, 2022 |

Oral Oncolytic Non-Adherence in Medically Integrated Dispensing Pharmacies
March 24, 2022 |

Oral Oncolytic Care Plans in Medically Integrated Dispensing Pharmacies
March 24, 2022 |

First-Of-Its-Kind Oncology State Legislation Tracking Tool
March 15, 2022 |

CTI BioPharma Announces FDA Accelerated Approval of VONJO™ (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
March 1, 2022 |

Federal Trade Commission Seeking Information on How PBMs Impact Practices and Patients
February 25, 2022 |

PBM REFORM BILL MAKING STRIDES IN VIRGINIA HOUSE OF REPRESENTATIVES
February 25, 2022 |

OVERWHELMING CONSENSUS IN HOUSE PUTS PBM BILL ON DOORSTEP
February 18, 2022 |

NCODA Stands United With Biden Administration On Cancer Moonshot
February 17, 2022 |

Neratinib (Nerlynx®) Diarrhea Management
February 16, 2022 |

New NDC number for TIBSOVO®
February 15, 2022 |

Fam-Trastuzumab deruxtecan-nxki (Enhertu®) Management
February 4, 2022 |

Durvalumab (Imfinzi®) Therapy Overview
February 4, 2022 |

Duvelisib (Copiktra®) for Chronic Lymphocytic Leukemia and Follicular Lymphoma
February 1, 2022 |

Selinexor (Xpovio®) Patient Management
February 1, 2022 |

Use of Isatuximab-irfc (Sarclisa®) in Patients with Relapsed Refractory Multiple Myeloma
January 28, 2022 |

Tivozanib (Fotivda®) for Relapsed or Refractory Advanced Renal Cell Carcinoma
January 18, 2022 |

Enfortumab Vedotin-ejfv (Padcev®) Management for Advanced or Metastatic Urothelial Carcinoma
January 14, 2022 |

NCODA Welcomes New Executive Council Members
January 12, 2022 |

Temozolomide (Temodar®) for Glioblastoma Multiforme
January 4, 2022 |

GOV. HOCHUL (NY) SIGNS BILL TO REGULATE PHARMACY BENEFIT MANAGERS
January 3, 2022 |

Ponatinib (Iclusig®) Patient Management
December 20, 2021 |

Managing EGFR Inhibitor Induced Rash
December 13, 2021 |

DPYD Testing Prior to Fluoropyrimidine Treatment
December 13, 2021 |

FGFR Inhibitor Side Effect Management
November 23, 2021 |

Regorafenib (Stivarga®) in Metastatic Colorectal Cancer
November 22, 2021 |

Comment On Proposed LCD DL37810
November 12, 2021 |

Vaccination for Non-Transplant Patients with Cancer
November 10, 2021 |

Mobocertinib (Exkivity™) Side Effect Management
November 8, 2021 |

Use of Belumosudil (Rezurock®) for the Treatment of Chronic Graft-Versus-Host Disease
November 5, 2021 |

Fostamatinib (Tavalisse®) Use in Chronic Immune Thrombocytopenia
November 4, 2021 |

Patients Are The Priority: A Call For A Medically Integrated Community
October 28, 2021 |

Cabazitaxel (Jevtana®) for Patients with Metastatic Castration-Resistant Prostate Cancer
October 28, 2021 |

Sorafenib (Nexavar) for the Treatment of Hepatocellular Carcinoma and Transition to Second-line Regorafenib (Stivarga®)
October 28, 2021 |

Management of Abemaciclib (Verzenio®) Associated Diarrhea
October 28, 2021 |

Advanced Breast Cancer: Appropriate Patient Identification with Abemaciclib (Verzenio®)
October 28, 2021 |

Going beyond the first fill: Prime Therapeutics, NCODA collaboration enables improved patient outcomes through new oncology pharmacy accreditation
October 19, 2021 |

A Win For Cancer Patients: First-of-Its-Kind Collaboration Between National Oncology Pharmacy Nonprofit and PBM
October 18, 2021 |

Advanced Systemic Mastocytosis Patient Diagnostic Algorithm
October 13, 2021 |

Selpercatinib (Retevmo®) Management
October 12, 2021 |

Trifluridine and Tipiracil (Lonsurf®) for Treatment of Gastric Cancer
October 12, 2021 |

Bortezomib (Velcade) Management for Multiple Myeloma and Mantle Cell Lymphoma
October 12, 2021 |

Regorafenib (Stivarga®) in the Treatment of Hepatocellular Carcinoma
October 8, 2021 |

Niraparib (Zejula): Dose Modifications Based on Weight and Platelet Counts
October 8, 2021 |

Selpercatinib (Retevmo®) Genomic Testing Management
October 8, 2021 |

Larotrectinib (Vitrakvi®) Overview
October 8, 2021 |

Avapritinib (Ayvakit®) Management for Gastrointestinal Stromal Tumor
October 7, 2021 |

Ruxolitinib (Jakafi®) in the Treatment of Polycythemia Vera
October 7, 2021 |

Gilteritinib (Xospata®) for Relapsed/Refractory Acute Myeloid Leukemia
October 7, 2021 |

Ibrutinib (Imbruvica®) Expansion with Obinutuzumab (Gazyva®)
October 5, 2021 |

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Radioactive Iodine-Refractory Differentiated Thyroid Cancer
October 5, 2021 |

Ripretinib (Qinlock®) for Treatment of Adults with Advanced Gastrointestinal Stromal Tumors
October 4, 2021 |

Ovarian Cancer: PARP Inhibitor Eligibility
October 1, 2021 |

Pralsetinib (Gavreto®) Management for Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
October 1, 2021 |

Managing Immunotherapy Treatment Related Rash
September 29, 2021 |

Trifluridine and Tipiracil (Lonsurf®) for Metastatic Colorectal Cancer
September 29, 2021 |

Copanlisib (Aliqopa™) for the Management of Relapsed/Refractory Follicular Lymphoma
September 28, 2021 |

Tucatinib (Tukysa®) Management
September 28, 2021 |

Avapritinib (Ayvakit®) Management for Advanced Systemic Mastocytosis
September 27, 2021 |

Oral Formulation of Decitabine and Cedazuridine (Inqovi®) for Hematological Malignancies
September 27, 2021 |

Daratumumab (Darzalex®) for Multiple Myeloma
September 27, 2021 |

Larotrectinib (Vitrakvi®) Genomic Testing Management
September 23, 2021 |

Acalabrutinib (Calquence®) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
September 23, 2021 |

Osimertinib (Tagrisso®) in EGFR Positive Non-Small Cell Lung Cancer
September 23, 2021 |

Takeda’s EXKIVITY™ (mobocertinib) Approved by U.S. FDA as the First Oral Therapy Specifically Designed for Patients with EGFR Exon20 Insertion+ NSCLC
September 22, 2021 |

Non-Small Cell Lung Cancer Stage III Overview and Patient Eligibility of Durvalumab (Imfinzi®)
September 22, 2021 |

Ruxolitinib (Jakafi®) in the Management of Myelofibrosis Patients
September 22, 2021 |

Copanlisib (Aliqopa™) Toxicity Management
September 21, 2021 |

Afatinib (Gilotrif®) Management for Non-Small Cell Lung Cancer
September 21, 2021 |

Zanubrutinib (Brukinsa®) Patient Selection and Management in Mantle Cell Lymphoma
September 20, 2021 |

Chemotherapy Induced Nausea and Vomiting
September 16, 2021 |

Management of Alpelisib (Piqray®) Induced Hyperglycemia
September 16, 2021 |

Oral Chemotherapy Induced Peripheral Neuropathy
September 16, 2021 |

Olanzapine (Zyprexa) in Chemotherapy Induced Nausea and Vomiting
September 16, 2021 |

Patient Screening for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
September 16, 2021 |

Ixazomib (Ninlaro®) in the Treatment of Multiple Myeloma
September 16, 2021 |

Cemiplimab-rwlc (Libtayo®) Patient Management
September 14, 2021 |

OPDIVO® is now available in a 120-mg/120mL vial.
September 14, 2021 |

Loncastuximab tesirine-lply (Zynlonta®) in Relapsed/Refractory Large B-Cell Lymphoma
September 13, 2021 |

Brentuximab Vedotin (Adcetris®): Neuropathy and Neutropenia Management
September 13, 2021 |

Olaparib (Lynparza®) Clinical Management
September 13, 2021 |

Liposomal Daunorubicin-Cytarabine (Vyxeos®) Management
September 13, 2021 |

Ibrutinib (Imbruvica®) Management
September 13, 2021 |

Oncolytic Induced Diarrhea
September 10, 2021 |

Chemotherapy, Oncolytic, Antiemetic Induced Constipation
September 10, 2021 |

Opioid Induced Constipation
September 10, 2021 |

Non-hormonal Birth Control Alternative with Lactic acid/Citric acid/Potassium Bitartrate (Phexxi®)
September 10, 2021 |

Proactive Symptom Management in Myelofibrosis
September 10, 2021 |

Drug Induced Hand‐Foot Syndrome
September 9, 2021 |

Granisetron (Sancuso®) Transdermal System for Chemotherapy Induced Nausea and Vomiting
September 9, 2021 |

Darolutamide (Nubeqa®) in the Treatment of Non-Metastatic Castration Resistant Prostate Cancer
September 8, 2021 |

Telotristat Ethyl (Xermelo®) for the Management of Carcinoid Syndrome Diarrhea
September 7, 2021 |

Stomatitis Prophylaxis During Everolimus (Afinitor®) Therapy
September 7, 2021 |

Use of Rucaparib (Rubraca®) In the Treatment of Ovarian, Fallopian Tube, Primary Peritoneal or Prostate Cancer
September 7, 2021 |

Enzalutamide (Xtandi®) for patients with castration-resistant prostate cancer or metastatic castration-sensitive prostate cancer
September 7, 2021 |

Trilaciclib (Cosela™) Management
September 7, 2021 |

Lurbinectedin (ZepzelcaTM) for Small Cell Lung Cancer
September 3, 2021 |

NCODA Expands Patient and Caregiver Resource to Improve Understanding and Outcomes
September 1, 2021 |

Netupitant/Fosnetupitant and Palonosetron (Akynzeo®) for Chemotherapy-Induced Nausea and Vomiting
August 11, 2021 |

NCODA Structures Medically Integrated Pharmacy Accreditation
August 10, 2021 |

BIDEN ADMINISTRATION PROPOSES WITHDRAW FROM MOST FAVORED NATION
August 9, 2021 |

Florida Cancer Specialists & Research Institute to mandate COVID-19 vaccines for its workforce
August 9, 2021 |

Tafasitamab-cxix (Monjuvi®) for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
August 5, 2021 |

FDA Approves Dose Escalation Label Update for Puma Biotechnology’s NERLYNX® (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer
August 2, 2021 |

Epizyme Launches EZH2Now Testing Program with Quest Diagnostics for Relapsed or Refractory Follicular Lymphoma Patients
July 27, 2021 |

CoPay Accumulator Patient Resources
July 15, 2021 |

LOUISIANA SIGNS LAW TO PROHIBIT WHITE BAGGING
June 29, 2021 |

KITE ANNOUNCES YESCARTA® CAR T-CELL THERAPY IMPROVED EVENT-FREE SURVIVAL BY 60% OVER CHEMOTHERAPY PLUS STEM CELL TRANSPLANT IN SECONDLINE RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA
June 28, 2021 |

Bayer Introduces Updated Packaging for Stivarga® (regorafenib) to Help Accommodate Dispensing
June 24, 2021 |

NORTH CAROLINA PUSHING TO ENHANCE CONTINUITY OF CARE
June 18, 2021 |

FDA Approves Blueprint Medicines’ AYVAKIT™ (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis
June 17, 2021 |

NEW YORK STATE PUSHES ONCOLOGY MOMENTUM FORWARD
June 11, 2021 |

Karyopharm Announces XPOVIO® (selinexor) Is Now Available in Additional Strength Tablets
June 10, 2021 |

TENNESSEE REGULATES PBM; WIN FOR ONCOLOGY PATIENTS
June 8, 2021 |

GOV. ABBOTT (TX) SIGNS PBM LEGISLATION – A VICTORY FOR ONCOLOGY PATIENTS
May 27, 2021 |

RYBREVANTTM (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
May 24, 2021 |

NCODA Welcomes New Executive Council Member
May 20, 2021 |

LEGISLATIVE VICTORIES FOR ONCOLOGY PATIENTS IN ALABAMA & OKLAHOMA
May 17, 2021 |

TAKING A STAND FOR TEXANS WITH CANCER
May 12, 2021 |

Patient Access Network (PAN) Foundation | Patient Assistance Funds
May 6, 2021 |

Takeda Announces U.S. FDA Grants Priority Review for New Drug Application for Mobocertinib (TAK-788) as a Treatment for EGFR Exon20 Insertion+ Metastatic Non-Small Cell Lung Cancer
April 29, 2021 |

FDA Approves Immunotherapy for Endometrial Cancer with Specific Biomarker
April 26, 2021 |

NCODA Welcomes New Executive Council Member – Lucius Daniel, PharmD
April 26, 2021 |

FDA approves Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma
April 12, 2021 |

AVEO Oncology Announces U.S. Commercial Availability of FOTIVDA® (tivozanib) for the Treatment of Adult Patients With Relapsed or Refractory Advanced Renal Cell Carcinoma Ahead of Previous Guidance
March 23, 2021 |

U.S. FDA Approves Yescarta® for Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic Therapy
March 8, 2021 |

Now Approved: PEPAXTO® (melphalan flufenamide); Oncopeptides, Inc.
March 5, 2021 |

ANY WILLING PROVIDER (AWP) – STILL A MAJOR ISSUE IN ONCOLOGY
February 23, 2021 |

FDA approves Libtayo® (cemiplimab-rwlc) monotherapy for patients with first-line advanced non-small cell lung cancer with PD-L1 expression of ≥50%
February 23, 2021 |

Larotrectinib (Vitrakvi®) Overview
February 12, 2021 |

NCODA Welcomes Collaboration with Evofem Biosciences to Educate Oncology Community about Phexxi® – A Non-Hormonal Birth Control Option for Women with Cancer
February 10, 2021 |

NCODA Welcomes Five New Executive Council Members
February 8, 2021 |

Evofem Biosciences and NCODA Announce Collaboration to Educate Oncology Community about Phexxi®, A Non-Hormonal Birth Control Option for Women with Cancer
February 4, 2021 |

Exelixis announces FDA approval for CABOMETYX(R) (cabozantinib) with OPDIVO(R) (nivolumab)
January 27, 2021 |

New Indication for ENHERTU® (fam-trastuzumab deruxtecan-nxki)
January 20, 2021 |

DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) Becomes the First FDA-Approved Treatment for Patients with Newly Diagnosed Light Chain (AL) Amyloidosis
January 19, 2021 |

Most Favored Nation: Temporary Restraining Order Issued
December 23, 2020 |

MOST FAVORED NATION MODEL: NOT THE ANSWER FOR PATIENTS
December 21, 2020 |

Tazemetostat (Tazverik®) Management in Relapsed/Refractory Follicular Lymphoma
December 18, 2020 |

SUPREME COURT RULES UNANIMOUS: REGULATES PHARMACY BENEFIT MANAGERS
December 11, 2020 |

Intermountain Healthcare
November 19, 2020 |

Use of Rasburicase (Elitek®) for Treatment of Tumor Lysis Syndrome
November 19, 2020 |

UnitedHealthcare (UHC) Announcement
November 16, 2020 |

National Broadcast: New Evidence in First-Line AML and Exploring Outcomes with Fixed-Duration Treatment in CLL
October 28, 2020 |

Oklahoma Cancer Specialists and Research Institute
October 9, 2020 |

Oncolytics Today Completes BPA Worldwide Initial Business Publication Audit
October 5, 2020 |

Beacon Cancer Care
September 11, 2020 |

Nubeqa Update – New Safety Data Poster Presented at ASCO
September 10, 2020 |

Approval of GAVRETO™ (pralsetinib)
September 8, 2020 |

Cone Health Cancer Center at Wesley Long
August 31, 2020 |

PTCE and NCODA to Partner in Bringing Oncology-Focused Continuing Education to the NCODA Membership
August 26, 2020 |

FDA granted accelerated approval to tazemetostat for follicular lymphoma
July 7, 2020 |

FDA approves selinexor for relapsed/refractory diffuse large B-cell lymphoma
June 29, 2020 |

Oncolytics Today Applies For BPA Worldwide Business Publication Membership
June 23, 2020 |

UNM Comprehensive Cancer Center
June 5, 2020 |

St. Elizabeth Healthcare
May 13, 2020 |

U.S. Food and Drug Administration Approves DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj), a New Subcutaneous Formulation of Daratumumab in the Treatment of Patients with Multiple Myeloma
May 4, 2020 |

Seattle Genetics Announces U.S. FDA Approval of TUKYSA™ (tucatinib) for People with Advanced Unresectable or Metastatic HER2-Positive Breast Cancer
April 21, 2020 |

Bristol Myers Squibb (BMS) Expanded Patient Support Program Overview
April 14, 2020 |

Clearview Cancer Institute
April 10, 2020 |

Oncology Consultants
March 24, 2020 |

**IMPORTANT UPDATE** NCODA SPRING FORUM 2020
March 9, 2020 |

FDA approves Sarclisa® (isatuximab-irfc) for patients with relapsed refractory multiple myeloma
March 3, 2020 |

Shenandoah Oncology
February 14, 2020 |

NCODA Announces the defining of the Medically Integrated Dispensing Pharmacy
January 27, 2020 |

Gettysburg Cancer Center
January 9, 2020 |

Houston Methodist Hospital Texas Medical Center
December 13, 2019 |


CALQUENCE® (acalabrutinib) Receives US FDA Approval for New Indication
November 25, 2019 |

University of Illinois Cancer Center
November 19, 2019 |

Bristol-Myers Squibb Announces CheckMate -227 Part 1a Meets Co-Primary Endpoint of Overall Survival
October 23, 2019 |

Trastuzumab deruxtecan granted FDA Priority Review for treatment of patients with HER2-positive metastatic breast cancer
October 21, 2019 |

FDA Approves Labeling Supplement for Puma Biotechnology’s NERLYNX® (neratinib) for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
October 3, 2019 |

University of Minnesota discovery is now a first-in-human clinical trial for leukemia
September 24, 2019 |

Miami Cancer Institute
September 17, 2019 |

Celgene announces Phase 3 successes for CC-486 for use as maintenance therapy in Acute Myeloid Leukemia.
September 13, 2019 |

Medically integrated pharmacies make patient care more efficient
September 9, 2019 |

U.S. FDA Approves INREBIC® (Fedratinib) as First New Treatment in Nearly a Decade for Patients With Myelofibrosis
August 29, 2019 |

Local pharmacist inspires patient-choice state law
August 27, 2019 |

Athenex Announces Oral Paclitaxel and Encequidar had a Significantly Higher Response Rate Over IV Paclitaxel in a Phase III Pivotal Study in Metastatic Breast Cancer
August 27, 2019 |

Arizona Blood & Cancer Specialists
August 15, 2019 |

Oregon passes PBM legislation
August 7, 2019 |

White House drops Drug Rebate Reform
July 12, 2019 |

Letter to the Committee on Finance – Phair Pricing Act (S.640)
July 2, 2019 |

CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer
July 2, 2019 |

NCODA Patient Surveys Support the Need for Medically Integrated Pharmacies
June 20, 2019 |

Statins reduce stroke risk in cancer patients
June 20, 2019 |

New Jersey Urology
June 18, 2019 |

SQ Administration of Daratumumab: New Option for Patients
June 17, 2019 |

Phair Pricing Act and DIR Fees
June 14, 2019 |

Congratulations to Norton Healthcare’s 2019 Nurses of the Year
May 17, 2019 |

CMS issues final Drug Pricing Rule
May 17, 2019 |

Virginia Cancer Institute
May 6, 2019 |

Proposal for the Step Therapy Process into Medicare Plans
May 1, 2019 |

Barry D. Brooks, M.D., Joins NCODA Executive Council
April 26, 2019 |

CMS to allow copay accumulators: when generics are available
April 21, 2019 |

Clinical Awareness Highlight: Ovarian Cancer
April 21, 2019 |

Senate hearing with PBMs misses the mark in oncology
April 10, 2019 |

Alabama Oncology
April 10, 2019 |

NCODA Welcomes Three New Executive Council Members
March 29, 2019 |

Landmark legislation blocks copay accumulators in VA
March 28, 2019 |

Compliance/Adherence with oral oncolytics: risk or benefit?
March 26, 2019 |

Florida Cancer Specialists Published in the Journal of Oncology Pharmacy Practice
March 25, 2019 |

NCODA Announces Dr. Mario Lacouture as Director of the Medical Advisory Board for Treatment Support Program
March 19, 2019 |

OptumRX / UHC to “pass rebates to more clients”
March 13, 2019 |

Summit Cancer Centers
March 12, 2019 |

Senate Finance Committee meeting with Pharma CEO’s today, 2/26/19
February 26, 2019 |

Women & Infants Hospital (Rhode Island)
February 14, 2019 |

Patient-Reported Outcomes: indicators for oncology drug-approvals
February 13, 2019 |

Rep. Doug Collins introduces legislation to lower drug costs
February 8, 2019 |

CREATES Act revived in Congress
February 7, 2019 |

Aspirin use in HCC and Ovarian Cancer
February 4, 2019 |

Anthem will launch in-house PBM in second-quarter 2019
February 1, 2019 |

HHS Proposal Reforms Drug Rebates to Reduce Patient Spending
February 1, 2019 |

Patient Adherence, a Challenge of Oral Chemotherapy
January 22, 2019 |

The Benefits of Medically Integrated Dispensing for Cancer Drugs
January 22, 2019 |

Arizona Oncology
January 14, 2019 |

Southern Oncology Specialists
December 19, 2018 |

Simmons Cancer Institute at SIU Medicine
November 6, 2018 |

NCODA Announces: Oncology Pharmacy Technician Association (OPTA)
October 23, 2018 |

Texas Oncology
October 12, 2018 |

Directions in Oncology Pharmacy®
October 2, 2018 |

Financial impact from in-office dispensing of oral chemotherapy
September 25, 2018 |

Dr Ali McBride: Addressing Adherence Issues With Patient Education
September 25, 2018 |

The Medicare Patient’s Journey: Finding Financial Assistance for Prescription Medications
September 25, 2018 |

Venetoclax (Venclexta®) Risk Stratification, Dosing, and Dispensing Procedure
September 22, 2018 |

American Society of Clinical Oncology Position Statement: Pharmacy Benefit Managers and Their Impact on Cancer Care
September 6, 2018 |

Smilow Cancer Hospital – Yale New Haven Health
September 4, 2018 |

Billings Clinic Cancer Center
August 10, 2018 |

Missouri Cancer Associates
August 10, 2018 |

Memorial Cancer Institute
August 10, 2018 |

Bassett Healthcare Network Bassett Medical Center
June 22, 2018 |

Helping Patients Faced with CoPay Accumulator Changes
June 20, 2018 |

Taiho Oncology Eliminates Co-Pays for Many of the Patients Treated with LONSURF® (trifluridine and tipiracil)
June 16, 2018 |

Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
June 5, 2018 |

ASCO Selects NCODA Abstract for Publication: Cost Avoidance & Waste Tracker
May 27, 2018 |

New England Cancer Specialists
May 13, 2018 |

Hematology Oncology Associates of Central New York
May 13, 2018 |

Joliet Oncology-Hematology Associates, Ltd. And Presence Cancer Care
May 13, 2018 |

Tri-County Hematology Oncology Associates
May 10, 2018 |

NCODA Member Practice Goes Live with Medically Integrated Dispensary
April 26, 2018 |

Patient Care Provider and Patient Burdens of Obtaining Oral Anticancer Medications
April 26, 2018 |

With the Oncology Care Model, “Everyone Has to Be Engaged,” Including Patients
April 24, 2018 |

Provider and Patient Burdens of Obtaining Oral Anticancer Medications
April 21, 2018 |

NCODA Members in Action
April 20, 2018 |

Designing Best Practices to Better Manage Patients on Oral Cancer Medications
April 19, 2018 |

Pacific Shores Medical Group
April 19, 2018 |

Abemaciclib effective as initial therapy for certain women with advanced breast cancer
April 18, 2018 |

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule
April 17, 2018 |

Oral Chemotherapy Education Makes Impact at Texas Oncology Stakeholder Meeting
April 16, 2018 |

Nominations Open for Living the Mission Award
April 2, 2018 |

Texas Oncology Receives PBMI 2018 Excellence Award
April 1, 2018 |

Oncology Nurse Navigators: Putting the Value in Value-Based Payment Models
March 30, 2018 |

Copay Accumulators: Costly Consequences of a New Cost-Shifting Pharmacy Benefit
March 28, 2018 |

New “Let’s Talk About Cost” Ads Highlight How Copay Accumulator Programs Leave Patients Financially Exposed
March 26, 2018 |

The Ghosh Center for Oncology & Hematology
March 22, 2018 |

Cancer Partners of Nebraska
March 22, 2018 |

Coalition to Improve Access to Cancer Care (CIACC)
March 20, 2018 |

Physician Dispensing – Adding value to patients and the practice
March 10, 2018 |


When Things Unexpectedly Work Out
March 10, 2018 |

Better Care for Cancer Patients Motivates NCODA Members
March 7, 2018 |

Utah Cancer Specialists
February 22, 2018 |

Passionate Financial Support – An Antidote for Financial Toxicity
February 1, 2018 |

Virginia Cancer Specialists
January 22, 2018 |

An Innovative Platform for Oncology Practice Collaboration
October 30, 2017 |

Letter from Congress: Ensuring Rebates and Discounts in Medicare Part D Help Reduce Patient OOP Costs
October 12, 2017 |

OncLive® Expands Strategic Alliance Partnership Program With the National Community Oncology Dispensing Association
August 16, 2017 |

EGFR Inhibitors
April 11, 2017 |

Chronic Lymphocytic Leukemia with Del17p
April 11, 2017 |

DIRs: PBMs Pay Less Each Year While Prices Go Up
March 20, 2017 |

Update Patient Survey (English & Spanish)
March 15, 2017 |

NCODA Spring Forum Agenda
February 22, 2017 |

Implementing Oral Oncolytics: Steps to Success
November 30, 2016 |

Big victory for Oncology Patients! – CVS pulls back on closing out in office dispensing.
October 31, 2016 |

PIF: Utah Cancer Specialists
June 1, 2016 |

Practice in Focus: Virginia Cancer Specialist (VCS)
May 14, 2016 |

NCODA Payor Update!
May 11, 2016 |

Waste in Cancer Drugs Costs $3 Billion a Year, a Study Says
May 11, 2016 |

ONS:Edge White Paper: How to Overcome Adherence Challenges in Patients Taking Oral Therapy for mCRC
March 3, 2016 |

Antiemesis Prophylaxis Remains Inadequate
March 2, 2016 |

Medicines in Development for Cancer
March 1, 2016 |

Iowa Teen Can’t Get Chemotherapy Drug Due to CVS Issue
January 26, 2016 |

NCODA’s Positive Quality Interventions: Breast Cancer
May 5, 2015 |

Specialty Pharmacies Proliferate
May 3, 2015 |

What Is a Navigator?
May 2, 2015 |

NCODA – Celebrating 1 year…success builds success…continuing to re-define the patient-centered model for the optimal management of oral cancer drug therapy.
April 24, 2015 |

NCODA – Leading a new standard in optimizing quality patient care to cancer patients receiving oral therapy.
March 20, 2015 |
RESOURCES
Cost Avoidance Waste Tracker
PQI in Action
OCE Sheets
IVE Sheets
Treatment Support Kits
PQI Podcast
Members
Member Resources
OPTA
Committees
Member Login
Events
Webinars
Spring Forum
Oncology Institute
PSO Annual Meeting
Fall Summit
315-655-4640
P.O. Box 468
Cazenovia, NY 13035